Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Crohn's disease
Last updated March 29, 2019
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated March 29, 2019
Movapo (apomorphine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Parkinson's disease
Last updated March 27, 2019
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Renal Cell Carcinoma
Last updated March 20, 2019
Opdivo-Yervoy (nivolumab-ipilimumab)
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Metastatic Melanoma
Last updated March 20, 2019
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Hodgkin's Lymphoma
Last updated March 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Unresectable Hepatocellular Carcinoma
Last updated March 7, 2019
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-Cell Receptor Inhibitor (BCRi)
Last updated March 6, 2019
Status:
Concluded with an LOI
Manufacturer:
Apobiologix, a Division of Apotex Inc.
Indication:
Febrile Neutropenia
Last updated February 28, 2019
Status:
Concluded with an LOI
Manufacturer:
Sanofi-Aventis Canada Inc.
Indication:
Rheumatoid Arthritis
Last updated February 26, 2019